Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents
Top Cited Papers
Open Access
- 13 October 2020
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 142 (15), 1425-1436
- https://doi.org/10.1161/circulationaha.120.046308
Abstract
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents remains uncertain. We compared short-term (12-month) DAPT after percutaneous coronary intervention with drug-eluting stents. Methods: Twenty-four randomized, controlled trials were selected using Medline, Embase, Cochrane library, and online databases through September 2019. The coprimary end points were myocardial infarction and major bleeding, which constituted the net clinical benefit. A frequentist network meta-analysis was conducted with a random-effects model. Results: In 79 073 patients, at a median follow-up of 18 months, extended-term DAPT was associated with a reduced risk of myocardial infarction in comparison with 12-month DAPT (absolute risk difference, –3.8 incident cases per 1000 person-years; relative risk, 0.68 [95% CI, 0.54–0.87]), midterm DAPT (absolute risk difference, –4.6 incident cases per 1000 person-years; relative risk, 0.61 [0.45–0.83]), and short-term DAPT followed by aspirin monotherapy (absolute risk difference, –6.1 incident cases per 1000 person-years; relative risk, 0.55 [0.37–0.83]), or P2Y12 inhibitor monotherapy (absolute risk difference, –3.7 incident cases per 1000 person-years; relative risk, 0.69 [0.51–0.95]). Conversely, extended-term DAPT was associated with a higher risk of major bleeding than all other DAPT groups. In comparison with 12-month DAPT, no significant differences in the risks of ischemic end points or major bleeding were observed with midterm or short-term DAPT followed by aspirin monotherapy, with the exception that short-term DAPT followed by P2Y12 inhibitor monotherapy was associated with a reduced risk of major bleeding. There were no significant differences with respect to mortality between the different DAPT strategies. In acute coronary syndrome, extended-term in comparison with 12-month DAPT was associated with a reduced risk of myocardial infarction without a significant increase in the risk of major bleeding. Conclusions: The present network meta-analysis suggests that, in comparison with 12-month DAPT, short-term DAPT followed by P2Y12 inhibitor monotherapy reduces major bleeding after percutaneous coronary intervention with drug-eluting stents, whereas extended-term DAPT reduces myocardial infarction at the expense of more bleeding events.This publication has 50 references indexed in Scilit:
- A New Strategy for Discontinuation of Dual Antiplatelet TherapyJournal of the American College of Cardiology, 2012
- Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary StentingCirculation, 2012
- Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting StentsCirculation, 2012
- 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesYearbook of Cardiology, 2012
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting StentsThe New England Journal of Medicine, 2010
- Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA TrialJournal of the American College of Cardiology, 2007
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic EventsThe New England Journal of Medicine, 2006
- Updated Method Guidelines for Systematic Reviews in the Cochrane Collaboration Back Review GroupSpine, 2003
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996